Journal: ESMO Open
Article Title: Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer
doi: 10.1016/j.esmoop.2024.104000
Figure Lengend Snippet: CLDN18.2 positivity in individual TMA cores and intratumoral heterogeneity. (A) CLDN18.2 positivity rates in each single TMA core (cores A, B, C, and D), as well as the positivity rate in at least one of these cores (positive in ≥1 core). (B) The results of CLDN18.2 immunohistochemistry in 111 cases where CLDN18.2 was positive in at least one core. Homogeneous positivity in all four TMA cores was observed in 43 cases (38.7%) and heterogeneous positivity (different results between TMA cores) occurred in the remaining 68 cases (61.3%). CLDN18.2, claudin 18.2; TMA, tissue microarray.
Article Snippet: Of the 400 advanced GC cases, 286 surgically collected samples were used to construct tissue microarray (TMA) blocks (Superbiochips Laboratories, Seoul, Korea) ( ).
Techniques: Immunohistochemistry, Microarray